Page last updated: 2024-12-08

4-trifluoromethylsalicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-trifluoromethylsalicylic acid: structure given in first source; metabolite of triflusal [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164578
CHEMBL ID3244577
CHEBI ID174020
SCHEMBL ID115659
MeSH IDM0103900

Synonyms (47)

Synonym
2-hydroxy-4-trifluoromethyl benzoic acid
2-hydroxy-4-(triluoromethyl)benzoic acid
CHEBI:174020
STK377474
2-hydroxy-4-(trifluoromethyl)benzoic acid
4-trifluoromethylsalicylic acid
T2064
328-90-5
4-(trifluoromethyl)salicylic acid
AKOS003368342
2-hydroxy-4-trifluoromethylbenzoic acid
benzoic acid, 2-hydroxy-4-(trifluoromethyl)-
4-tfmsa
uky7yre9e9 ,
unii-uky7yre9e9
FT-0601285
4-trifluoromethyl salicylic acid
c8h5f3o3
desacetyl triflusal-13c6
p-(trifluoromethyl)salicylic acid
4-trifluoromethyl-2-hydroxybenzoic acid
2-hydroxy-4-trifluoromethyl-benzoic acid
CHEMBL3244577
SCHEMBL115659
AM84126
FS-2331
4-trifluoromethylsalicylicacid
4-trifluoro methyl salicylic acid
mfcd01529657
desacetyl triflusal
J-509625
2-hydroxy-4-(trifluoromethyl)benzoic acid, aldrichcpr
DTXSID00186474
AC-8128
1246817-12-8
2-hydroxy-4-(trifluoromethyl)benzoic acid (4-(trifluoromethyl)salicylic acid)
SY002112
CS-W015348
BCP24443
triflusal impurity b
SB36620
triflusal impurity b [ep impurity]
EN300-126593
BKA30032
HY-W014632
desacetyltriflusal-13c6
Z1269108938

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs)."( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011
)
0.37
" Safety was assessed by adverse events, ECG, laboratory testing, and vital signs."( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal."( Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
Forn, J; Gorina, E; Jané, F; Mis, R; Ramis, J; Torrent, J,
)
0.13
" No significant differences were observed between the elimination half-life obtained after the single dose and after the two repeated dose regimens studied."( Pharmacokinetics of triflusal after single and repeated doses in man.
Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J, 1990
)
0.28
"The pharmacokinetic and pharmacodynamic profiles of the two triflusal formulations met the requirements for bioequivalence and non-inferiority, respectively."( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011
)
0.37
"The objective of this study was to evaluate the pharmacokinetic parameters of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), following a single oral dose of 900 mg in healthy subjects under fed and fasting conditions."( Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
Ding, LK; Ding, Y; Ge, J; Jia, YY; Lu, CT; Song, W; Song, Y; Wen, AD; Yang, J, 2015
)
0.42
"The mean Cmax of triflusal and HTB were 13."( Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
Ding, LK; Ding, Y; Ge, J; Jia, YY; Lu, CT; Song, W; Song, Y; Wen, AD; Yang, J, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"ss) during the multiple dosage regimen of 300 mg every 8 h, and 131 micrograms."( Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
Conte, L; Forn, J; Mis, R; Ramis, J, 1992
)
0.28
"Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship between plasma levels and dosage patterns."( Pharmacokinetics of triflusal after single and repeated doses in man.
Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J, 1990
)
0.28
"Following oral dosing under fasting condition, triflusal is promptly absorbed and rapidly depleted from the systemic circulation."( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxybenzoic acidAny benzoic acid carrying one or more phenolic hydroxy groups on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1136197Antiinflammatory activity against carrageenan-induced foot edema in rat at 400 mg/kg administered via gastric gavage1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (11.11)18.7374
1990's6 (13.33)18.2507
2000's11 (24.44)29.6817
2010's6 (13.33)24.3611
2020's17 (37.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.18 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (10.87%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.17%)0.25%
Other39 (84.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]